MedTrace Logo

Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV)

NCT02860858 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-10-23

No results posted yet for this study

Summary

Objective: To evaluate the efficacy of intravitreal aflibercept injection on visual acuity in patients with symptomatic macular PCV.

Conditions

  • Symtomatic Macular Polypoidal Choroidal Vasculopathy

Interventions

BIOLOGICAL

Intravitreous aflibercept injection

Sponsors & Collaborators

  • Department of Medical Services Ministry of Public Health of Thailand

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-12-30
Primary Completion
2018-08-30
Completion
2018-12-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02860858 on ClinicalTrials.gov